<html lang="en"><head>
  <meta charset="utf-8">
  <meta content="width=device-width, initial-scale=1.0" name="viewport">

  <title>VHL in ccRCC</title>
  <meta content="" name="description">
  <meta content="" name="keywords">

  <!-- Favicons -->
  <link href="../assets/img/favicon.png" rel="icon">
  <link href="../assets/img/apple-touch-icon.png" rel="apple-touch-icon">

  <!-- Google Fonts -->
  <link href="https://fonts.googleapis.com/css?family=Open+Sans:300,300i,400,400i,600,600i,700,700i|Raleway:300,300i,400,400i,500,500i,600,600i,700,700i|Poppins:300,300i,400,400i,500,500i,600,600i,700,700i" rel="stylesheet">

  <!-- Vendor CSS Files -->
  <link href="../assets/vendor/bootstrap/css/bootstrap.min.css" rel="stylesheet">
  <link href="../assets/vendor/icofont/icofont.min.css" rel="stylesheet">
  <link href="../assets/vendor/remixicon/remixicon.css" rel="stylesheet">
  <link href="../assets/vendor/owl.carousel/assets/owl.carousel.min.css" rel="stylesheet">
  <link href="../assets/vendor/boxicons/css/boxicons.min.css" rel="stylesheet">
  <link href="../assets/vendor/venobox/venobox.css" rel="stylesheet">

  <!-- Template Main CSS File -->
  <link href="../assets/css/style.css" rel="stylesheet">
</head>

<body>

<!-- ======= Portfolio Details ======= -->
<main id="main">
  <div id="portfolio-details" class="portfolio-details">
    <div class="container">

      <div class="row">
        <div class="col-lg-12 portfolio-info">
          <br>
          <h2 style="color:#12d640">VHL mutations in ccRCC and their impact on prognosis and treatment outcomes</h2>

          <ul>
            <li><strong>Publication Status</strong>: In Press</li>
          </ul>

          <p>
            <strong>Background:</strong><br>
            Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. Mutations in the
            von Hippel–Lindau (VHL) gene are the most frequent genetic alterations, while chromosome 3p (chr3p) loss—impacting
            tumor suppressors such as <em>VHL</em>, <em>PBRM1</em>, <em>SETD2</em>, and <em>BAP1</em>—is the most prevalent copy number alteration (CNA).
            Although both lead to VHL deficiency, their distinct roles in tumor development remain incompletely understood.
          </p>

          <p>
            <strong>Methods:</strong><br>
            We developed transcriptomic signatures reflecting VHL mutations and chr3p loss using The Cancer Genome Atlas (TCGA).
            These signatures capture dysregulated oncogenic pathways beyond mutation status alone. We evaluated their prognostic
            significance across multiple clinical ccRCC datasets.
          </p>

          <p>
            <strong>Results:</strong><br>
            VHL mutation status alone was not prognostic; however, a transcriptomic VHL signature score correlated with improved outcomes.
            Chr3p loss exerted a stronger transcriptomic effect and was associated with an immune “cold” microenvironment. In clinical data,
            the VHL signature predicted likelihood of response to targeted therapy (e.g., sunitinib), whereas the chr3p loss signature
            associated with increased sensitivity to immunotherapy.
          </p>

          <p>
            <strong>Conclusions:</strong><br>
            Distinct genomic alterations affecting VHL produce different molecular programs and clinical outcomes. While VHL mutations
            minimally impact the tumor immune milieu, CNA-driven VHL loss (chr3p loss) fosters immunosuppression, aligning with
            divergent treatment responses.
          </p>
        </div>
      </div>

    </div>
  </div><!-- End Portfolio Details -->
</main><!-- End #main -->

<!-- Vendor JS Files -->
<script src="../assets/vendor/jquery/jquery.min.js"></script>
<script src="../assets/vendor/bootstrap/js/bootstrap.bundle.min.js"></script>
<script src="../assets/vendor/jquery.easing/jquery.easing.min.js"></script>
<script src="../assets/vendor/php-email-form/validate.js"></script>
<script src="../assets/vendor/waypoints/jquery.waypoints.min.js"></script>
<script src="../assets/vendor/counterup/counterup.min.js"></script>
<script src="../assets/vendor/owl.carousel/owl.carousel.min.js"></script>
<script src="../assets/vendor/isotope-layout/isotope.pkgd.min.js"></script>
<script src="../assets/vendor/venobox/venobox.min.js"></script>

<!-- Template Main JS File -->
<script src="../assets/js/main.js"></script>

</body>
</html>
